A co-delivery system based on chlorin e6-loaded ROS-sensitive polymeric prodrug with self-amplified drug release to enhance the efficacy of combination therapy for breast tumor cells

Wang, Cui; Yang, Xiaoqing; Qiu, Haibao; Huang, Kexin; Xu, Qian; Zeng, Bin; Zhang, Lulu; Zhou, Man; Yi, Xiaoqing

doi:10.3389/fbioe.2023.1168192

Cited by 6 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate the ability of FeMOF@HA and PyroFPSH to generate reactive oxygen species (ROS) in cells upon exposure to light, we used 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA), a ROS probe that emits green fluorescence in the presence of ROS (Li et al, 2021;Wang et al, 2023). This feature was utilized in our investigations using confocal laser scanning microscopy (CLSM).…”

Section: Validation Of the Multienzyme-like Activitiesmentioning

confidence: 99%

Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment

Lv,

Fu,

You

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Overcoming resistance to apoptosis is a major challenge in cancer therapy. Recent research has shown that manipulating mitochondria, the organelles critical for energy metabolism in tumor cells, can increase the effectiveness of photodynamic therapy and trigger apoptosis in tumor cells. However, there is currently insufficient research and effective methods to exploit mitochondrial damage to induce apoptosis in tumor cells and improve the effectiveness of photodynamic therapy. In this study, we present a novel nanomedicine delivery and therapeutic system called PyroFPSH, which utilizes a nanozymes-modified metal-organic framework as a carrier. PyroFPSH exhibits remarkable multienzyme-like activities, including glutathione peroxidase (GPx) and catalase (CAT) mimicry, allowing it to overcome apoptosis resistance, reduce endogenous glutathione levels, and continuously generate reactive oxygen species (ROS). In addition, PyroFPSH can serve as a carrier for the targeted delivery of sulfasalazine, a drug that can induce mitochondrial depolarization in tumor cells, thereby reducing oxygen consumption and energy supply in the mitochondria of tumor cells and weakening resistance to other synergistic treatment approaches. Our experimental results highlight the potential of PyroFPSH as a versatile nanoplatform in cancer treatment. This study expands the biomedical applications of nanomaterials as platforms and enables the integration of various novel therapeutic strategies to synergistically improve tumor therapy. It deepens our understanding of multienzyme-mimicking active nanocarriers and mitochondrial damage through photodynamic therapy. Future research can further explore the potential of PyroFPSH in clinical cancer treatment and improve its drug loading capacity, biocompatibility and targeting specificity. In summary, PyroFPSH represents a promising therapeutic approach that can provide new insights and possibilities for cancer treatment.

show abstract

Section: Validation Of the Multienzyme-like Activitiesmentioning

confidence: 99%

Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment

Lv,

Fu,

You

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…There is another research synthesizing ROS-responsive prodrug by linking PTX with polyethylene glycol (PEG) chains via thioketal linkers and then co-assembling with Ce6 to realize combined antitumor efficacy. [63] Moreover, hydrophobic drugs can be modified with some hydrophilic molecules like oligosaccharides to increase their stability and biocompatibility. In a recent study, a glycosylated dimeric CPT prodrug was synthesized and coassembled with Ce6 for targeted and fluorescence imagingguided chemo-photodynamic therapy.…”

Section: Cabazitaxel Dimer Linked With Thioketal Linkermentioning

confidence: 99%

Ce6 nanoassemblies: Molecular mechanism and strategies for combinational anticancer therapy

Liu,

Xu,

Lyu

et al. 2023

Aggregate

View full text Add to dashboard Cite

Nowadays, cancer has become the leading cause of death worldwide, driving the need for effective therapeutics to improve patient prognosis. Photodynamic therapy (PDT) has been widely applied as an antitumor modality, owing to its minimal invasiveness, localized tumor damage, and high safety profile. However, its efficacy is limited by poor stability of photosensitizers, inadequate tumor accumulation, and a complex tumor microenvironment. To overcome these challenges, extensive endeavors have been made to explore the co‐assembly of the widely used photosensitizer chlorin e6 (Ce6) with various functional small molecules to enhance pharmacodynamic activity. This review provides a comprehensive overview of current studies on Ce6‐based nanoparticles for effective PDT and precise delivery of functional molecules. The self‐assembly mechanism will be discussed in detail, with a focus on potential strategies for combinational therapy with PDT.

show abstract

“…In recent years, the field of combined cancer therapy has witnessed widespread utilization of nanotechnology-based drug delivery systems, aiming to reduce drug toxicity and enhance drug bioavailability ( Zhao et al, 2020 ; Yi et al, 2022 ; Jiang et al, 2023 ; Wang et al, 2023 ). These systems included liposomes ( Liu et al, 2022 ), polymer nanoparticles, and hydrogels.…”

Section: Introductionmentioning

confidence: 99%

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib

Zhang,

Li,

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cisplatin (CDDP) is widely used as one kind of chemotherapy drugs in cancer treatment. It functions by interacting with DNA, leading to the DNA damage and subsequent cellular apoptosis. However, the presence of intracellular PARP1 diminishes the anticancer efficacy of CDDP by repairing DNA strands. Olaparib (OLA), a PARP inhibitor, enhances the accumulation of DNA damage by inhibiting its repair. Therefore, the combination of these two drugs enhances the sensitivity of CDDP chemotherapy, leading to improved therapeutic outcomes. Nevertheless, both drugs suffer from poor water solubility and limited tumor targeting capabilities. To address this challenge, we proposed the self-assembly of two drugs, CDDP and OLA, through hydrogen bonding to form stable and uniform nanoparticles. Self-assembled nanoparticles efficiently target tumor cells and selectively release CDDP and OLA within the acidic tumor microenvironment, capitalizing on their respective mechanisms of action for improved anticancer therapy. In vitro studies demonstrated that the CDDP-OLA NPs are significantly more effective than CDDP/OLA mixture and CDDP at penetrating cancer cells and suppressing their growth. In vivo studies revealed that the nanoparticles specifically accumulated at the tumor site and enhanced the therapeutic efficacy without obvious adverse effects. This approach holds great potential for enhancing the drugs’ water solubility, tumor targeting, bioavailability, and synergistic anticancer effects while minimizing its toxic side effects.

show abstract

A co-delivery system based on chlorin e6-loaded ROS-sensitive polymeric prodrug with self-amplified drug release to enhance the efficacy of combination therapy for breast tumor cells

Cited by 6 publications

References 41 publications

Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment

Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment

Ce6 nanoassemblies: Molecular mechanism and strategies for combinational anticancer therapy

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib

Contact Info

Product

Resources

About